Twist Bioscience Co. (NASDAQ:TWST) Insider Dennis Cho Sells 806 Shares

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 806 shares of Twist Bioscience stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10. Following the sale, the insider now owns 112,221 shares of the company’s stock, valued at approximately $5,538,106.35. The trade was a 0.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Dennis Cho also recently made the following trade(s):

• On Friday, January 3rd, Dennis Cho sold 144 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total value of $6,564.96.
• On Friday, December 20th, Dennis Cho sold 316 shares of Twist Bioscience stock. The stock was sold at an average price of $44.90, for a total value of $14,188.40.
• On Monday, December 16th, Dennis Cho sold 133 shares of Twist Bioscience stock. The shares were sold at an average price of $46.81, for a total value of $6,225.73.
• On Friday, December 6th, Dennis Cho sold 367 shares of Twist Bioscience stock. The stock was sold at an average price of $52.70, for a total transaction of $19,340.90.
• On Monday, November 11th, Dennis Cho sold 1,507 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total transaction of $72,336.00.

Twist Bioscience Stock Performance

TWST opened at $53.70 on Friday. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The business has a 50-day moving average of $48.84 and a two-hundred day moving average of $46.32.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. Twist Bioscience’s revenue was up 24.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.75) earnings per share. Research analysts predict that Twist Bioscience Co. will post -2.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TWST has been the topic of several research reports. Barclays lowered their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 19th. Leerink Partners raised their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Robert W. Baird upped their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday. Wolfe Research started coverage on Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Finally, TD Cowen reissued a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and an average target price of $53.80.

Institutional Trading of Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the company. Thrivent Financial for Lutherans purchased a new stake in Twist Bioscience during the third quarter valued at about $43,992,000. State Street Corp lifted its stake in shares of Twist Bioscience by 19.9% in the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after purchasing an additional 526,028 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after purchasing an additional 521,272 shares during the period. Jennison Associates LLC increased its position in Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock worth $31,636,000 after purchasing an additional 302,884 shares in the last quarter. Finally, ARK Investment Management LLC raised its holdings in Twist Bioscience by 4.4% in the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock valued at $260,040,000 after buying an additional 237,772 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.